Immunitybio Inc annual operating income for fiscal TTM was -$253 million, an increase of 1.2% from -$256 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Operating Income (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | ($253M) | ($256M) | ($344M) | ($362M) | ($351M) | ($330M) | ($221M) | ($67M) | ($98M) | ($99M) | ($124M) | ($239M) | ($6M) | ($2M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Operating Income (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | ($62M) | ($70M) | ($65M) | ($56M) | ($71M) | ($64M) | ($69M) | ($80M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More IBRX metrics: Revenue · Gross Profit · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All IBRX financial statements → Interactive IBRX charts →
About TickerBase · Data methodology & sources · Privacy · Terms